CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.
Conjunctivitis - infective - Management
When should topical chloramphenicol be avoided?
- Do not use topical chloramphenicol:
- In people who have experienced myelosuppression during previous exposure to chloramphenicol.
- In people who have a blood dyscrasia, or who have a family history of blood dyscrasias.
- Concurrently with other myelotoxic drugs.
- In pregnant or breastfeeding women, as its safety has not been established.
- For prolonged periods, since it may increase the likelihood of sensitization and resistance.
[ABPI Medicines Compendium, 2008; ABPI Medicines Compendium, 2007b; ABPI Medicines Compendium, 2007a; BNF 54, 2007]
© NHS Institute for Innovation and Improvement